Biotech-Network with positive development - SciTrix

22-Mar-2004

Also after its second year of existence SciTrix, the network of small and medium-sized biotechnology service companies, can look back on a further positive development. The reduction of the number of employees, the stagnation or even decrease in turnover, a difficult climate for investments and the liquidation or takeover of companies characterized the general trend in the industry and the development of other Biotech-networks. In contradiction SciTrix has in all the important fields scored a solid growth.

The number of employees has increased from 40 at the end of 2002 up to 54 in December 2003. That equals an increase of 35%. During the same period of time the network's turnover grew 25%. Additionally one of the network's members has had a successful second round of financing. For the current year 2004 a similarly positive development is striven for and expected.

The network of first-class Biotech-service companies is an innovative, dynamic and entrepreneurial partnership of specialized companies with a joint project- and marketing management. SciTrix serves to bundle various areas of authority as well as to expand the network-companies' capacities in research, development and production. Partners of this excellent network are BioGenes (Berlin), BioProof (Munich), BIOSYNTAN (Berlin), InVivo (Hennigsdorf) and the Berlin-based Proteome Factory AG.

As a network of independent companies SciTrix deals among other things with peptide synthesis, the proteome and protein analysis, the expression, fermentation and production of recombinant proteins, with downstream processing as well as with the development and production of customised mono- and polyclonal antibodies with guarantee. They also deal with the development, validation and production of immunoassays, with GLP certified bioanalytics as well as with the organisation of GCP certified clinical and preclinical pharmacokinetic proofs. The spectrum of services offered by SciTrix is continuously extended.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous